3.3401
3.41%
0.1101
Dopo l'orario di chiusura:
3.34
-0.0001
-0.00%
Opthea Limited Adr Borsa (OPT) Ultime notizie
Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Opthea to Present Phase 3 Trial Update at J.P. Morgan Healthcare Conference - TipRanks
Opthea's Wet AMD Program to be Featured at FLORetina 2024 - The Manila Times
Opthea’s Wet AMD Program to be Featured at FLORetina 2024 - Yahoo Finance
Opthea Highlights Innovative Wet AMD Therapy - TipRanks
Opthea to Participate in Citi 2024 Global Healthcare Conference - Yahoo Finance
Opthea Limited to Engage Investors at Healthcare Conference - TipRanks
Opthea Limited Targets AMD Market with Sozinibercept - TipRanks
Opthea Appoints Kathy Connell to Board of Directors - The Manila Times
Opthea Appoints Kathy Connell to Board of Directors - GlobeNewswire Inc.
Opthea : Chairman’s Address to the 2024 Annual General Meeting Form 6 K - Marketscreener.com
Opthea Limited Announces Board Changes - Marketscreener.com
Opthea's Sozinibercept Shows Superior Results in Phase 2b Eye Disease Trial - StockTitan
Opthea's Wet AMD Program Featured at Ophthalmology Events - The Manila Times
Opthea (NASDAQ:OPT) Shares Up 1.7% – What’s Next? - Defense World
Opthea to Participate in November Investor Conferences - The Manila Times
Opthea : UPDATE Opthea to Participate in November Investor Conferences Form 6 K - Marketscreener.com
Opthea Limited Strengthens Leadership and Advances AMD Treatment - TipRanks
FY2025 EPS Estimates for Opthea Lifted by Leerink Partnrs - Defense World
OPTOpthea Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Is Opthea Limited (OPT) the Penny Stock with the Biggest Upside Potential According to Analysts? - Insider Monkey
Opthea Files Notice of Annual General Meeting - The Manila Times
Opthea Ltd stock soars to 52-week high, touches $4.95 - Investing.com India
Opthea Ltd stock soars to 52-week high, touches $4.95 By Investing.com - Investing.com South Africa
Opthea Wet AMD Program to be Presented at Innovate Retina - The Manila Times
Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025 - The Manila Times
Opthea Limited Announces Chief Financial Officer Changes - Marketscreener.com
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024 - The Manila Times
Opthea Advances Retinal Disease Treatments - TipRanks
Opthea Advances nAMD Treatment with Sozinibercept - TipRanks
Opthea Joins the S&P/ASX 300 Index - StockTitan
Opthea Limited (NASDAQ:OPT) Shares Sold by Victory Capital Management Inc. - Defense World
EX-99.1 - SEC.gov
Opthea Advances Toward Sozinibercept Commercialization - TipRanks
Opthea’s Sozinibercept Eyes Breakthrough in AMD Therapy - TipRanks
FY2025 EPS Estimates for Opthea Limited Boosted by HC Wainwright (NASDAQ:OPT) - Defense World
Research Analysts Set Expectations for Opthea Limited’s FY2029 Earnings (NASDAQ:OPT) - Defense World
Opthea Prepares for Phase 3 Results with Leadership Revamp - TipRanks
Opthea (NASDAQ:OPT) Given New $12.00 Price Target at HC Wainwright - Defense World
Opthea Limited Showcases Innovations at Investor Conferences - TipRanks
Opthea Limited: Revenues Up, Losses Widen - TipRanks
Opthea Reports Full-Year Financial Results and Business Updates - Morningstar
Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024 - Morningstar
Opthea Limited Showcases at Ophthalmology Event - TipRanks
'Blockbuster opportunity': This speculative ASX stock could rise 70% - The Motley Fool Australia
Opthea forms global medical advisory board for retinal diseases - Investing.com India
Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board - StockTitan
Why Atturra, Bravura, Core Lithium, and Opthea shares are racing higher today - The Motley Fool
Opthea’s Sozinibercept Shows Promise for Wet AMD - TipRanks
Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD - StockTitan
Opthea (NASDAQ:OPT) Shares Down 0.8% - Defense World
Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022 - The Globe and Mail
Opthea To Present at SVB Leerink Global Healthcare Conference - The Globe and Mail
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):